Clinical trial of Siddha Drug "Naga Chendhooram" for Diabetes

Phase II non-randomized open clinical evaluation of Siddha Drug "Naga Chendhooram" for Madhumegam (Type 2 Diabetes Mellitus)- in patients of both gender between age group of 30 to 60 years, attending OPD at AAGHIM attached with GSMC

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/08/020946

Enrollment

Registered

2019-08-28

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Naga Chendhooram: 100 mg twice a day with milk for 90 days Control Intervention1: Nil: Nil

Eligibility

Inclusion criteria

Inclusion criteria: Mandatory Fasting blood glucose-120 to 160 mg/do PP blood glucose- 180 to 280 mg/DL HbA1c- 6.5 to 9% Optional Polyuria Polyphagia Polydipsia Nocturia

Exclusion criteria

Exclusion criteria: Insulin dependent Diabetes mellitus Cardiovascular disease Diabetic nephropathy Diabetic retinopathy Pregnant women Lactating mothers Tuberculosis affected individuals HbA1c > 9%

Design outcomes

Primary

Measure	Time frame
Reduction in clinical symptoms Reduction in blood sugar and HbA1c level by atleast 20% or to maintain HbA1c level within 7%Timepoint: 90 days	—

Secondary

Measure	Time frame
Secondary outcome is assessed by comparing the safety parameters before and after treatmentTimepoint: 90 days	—

Countries

India

Contacts

Public ContactDr Jani Antony S

Government Siddha Medical College

sasirekha.siddha@gmail.com9444832728

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026